MaxCyte shares slip 5.7% on Genentech cell therapy license deal

MaxCyte Inc. entered a multi-platform technology license partnership with Genentech, a member of the Roche Group, to support cell therapy development across research, clinical, and manufacturing workflows, the companies said Tuesday.

The license provides Genentech with access to MaxCyte's ExPERT GTx platform and additional cell engineering technologies for ex vivo applications, covering multiple development programs from early discovery through current Good Manufacturing Practice (cGMP) production.

"Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing," Maher Masoud, President and Chief Executive Officer of MaxCyte, said. "This partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing."

MaxCyte's platform includes Flow Electroporation technology for cell engineering and SeQure gene editing characterization services, which assess editing outcomes to support therapeutic development. The Rockville, Maryland-based company has been operating for more than 25 years, providing enabling technologies for next-generation cell-based therapeutics.

The deal marks a significant validation for MaxCyte's platform, given Genentech's position as one of the largest biotechnology companies globally and its parent Roche's substantial cell therapy investments. Financial terms of the license were not disclosed.

MaxCyte shares traded at an undisclosed price Tuesday, falling 5.7% in a session that also saw Roche shares decline 0.95%. The broader cell therapy sector has attracted increasing investment as companies pursue CAR-T and other engineered cell approaches for oncology and autoimmune indications, with partnerships between platform providers and large pharma becoming a key strategy for accelerating development timelines.

This article is for informational purposes only and does not constitute investment advice.